A b s t r a c t
Schistocytes are circulating RBC fragments. Their presence in the blood is considered abnormal and indicates the possibility of a thrombotic microangiopathy (TMA), in particular, one of the two major syndromes of thrombocytopenic purpura (TTP) or hemolytic uremic syndrome (HUS), with an unfavorable prognosis in the absence of treatment. 1 The detection and quantification of schistocytes is, consequently, an urgent test with great diagnostic and therapeutic importance. 2 On the other hand, the counting of schistocytes often needs to be done on an iterative basis in the follow-up for medullary transplants (TMA is a vital risk if it occurs during a reaction of a transplant against the host). 3 Finally, their presence in heart valve recipients is evidence of dysfunction of the valve.
Meanwhile, the identification of schistocytes remains difficult because the shapes to which they correspond are still under discussion. A consensus report was prepared recently by the Groupe Français d'Hématologie Cellulaire (GFHC [French Group of Cellular Hematology]). 4 Automated hematology systems permit one to obtain precise cellular counts on an urgent basis. The ADVIA 120 analyzer (Bayer Health Care, Tarrytown, NY) is the first to offer the possibility of direct measurement of abnormal RBCs and RBC fragments.
We compared schistocyte counts performed by different biologists and technicians with the automated counts by the ADVIA 120. The objective was to compare the results obtained by the analyzer (RBC fragments) with those obtained by the usual microscopic count using stained blood smears. Then we oriented our study more clinically to compare automated schistocyte detection with presence or absence of thrombotic disease. Because a link between the severity of thrombocytopenia and the TMA prognosis has been found, 5 we also studied the relationship between the percentage of schistocytes and the number of platelets. Our study validates the automated count provided by the analyzer. Nevertheless, a blood smear examination remains necessary to confirm the presence of schistocytes.
Materials and Methods

Samples
Schistocyte counting has been done by 2 methods: (1) from stained blood smears using the May-Grünwald Giemsa technique and an optical microscope and (2) by direct measurement of RBC fragments in a blood sample on the ADVIA 120 analyzer.
The 131 specimens originated from patients suspected of having TMA (TTP, HUS, transplants) or with heart valve dysfunction. The blood samples were obtained in an EDTAanticoagulated tube (Vacutainer, Becton Dickinson, San Jose, CA). All results, positive or negative in regard to schistocytes, were analyzed.
Optical Counting
Schistocyte counting was done on the smears according to the recommendations proposed by the GFHC: observations of 1,000 RBCs within their proper spreading zone (no overlap and excluding the feather edge area). Only triangular or helmet-shaped cells were kept as valid. The observers were chosen according to various levels of expertise in morphologic examination: specialized laboratory technician (M.D.), routine technician, student biologist (S.S.), versatile biologist (M.B.), and "expert" (J.-F.L.). Each observer had been instructed previously on the method recommended by the GFHC (S.S., participation in the investigation; M.D., M.B., and the routine technician, training workshop supervised by J.-F.L.).
Automated Counting
On the ADVIA 120, the identification of RBC fragments is performed by the integrated analysis of RBCs and platelets. The platelet scatter cytogram is formed by pairing light scatter signals acquired at low angle (2°-3°) and at high angle (5°-15°) that are converted into volume and refractive index values. The platelet scatter cytogram displays cells with volumes up to 30 fL and refractive indices between 1.35 and 1.40. The integrated analysis permits distinction of platelets (normal and large) and RBCs (microcytes, fragments, and ghosts). The RBC fragments correspond to events of volume smaller than 30 fL and with a refractive index greater than 1.40. The analyzer provides the RBC fragments above a threshold of 10,000/µL. The percentage of schistocytes subsequently was deduced based on the number of RBCs measured by the analyzer.
Statistics
The degree of agreement among the different observers and the analyzer was measured by using the intraclass correlation coefficient (ICCC) and was shown graphically by means of the Bland and Altman method. The sensitivity and specificity of the results provided by the analyzer were calculated by the usual methods (true and false positive and negative). For this calculation, the reference was the expert's count, with a positivity threshold set at 0.2%. The receiver operating characteristic (ROC) curve shows graphically the triggering percentage of RBC fragments (alarm threshold at maximum sensitivity). To evaluate the clinical impact of such data, we compared automated schistocyte detection with presence or absence of a thrombotic event by calculation of negative and positive predictive values (NPV and PPV, respectively) of the test. The agreement between the ADVIA 120 and the average of the observers gave an ICCC of 0.7274 (CI, 0.6285-0.8019). A graphic representation of the comparison of the schistocyte counts between the analyzer and the average of the observers is given in ❚Figure 1❚. It demonstrated that the ADVIA 120 had a tendency to overestimate the count (average, +0.445%). A shift existed corresponding to an appreciation error of the instrument (the worst result from a smear with very large anisopoikilocytosis with fragments of diverse shapes: RBC fragments, 15.5% but rarely actual schistocytes; J.-F.L., 1%; S.S., 1.4%). On 12 occasions, the observers obtained counts greater than those found by the analyzer (but only in 4 cases was the difference >0.5%; the maximum difference was 9% for the ADVIA 120 vs 12% for J.-F.L. and 13.5% for S.S.).
Results
Agreement Between Observers and Analyzer
Diagnostic Value of the Analyzer in Relation to the Microscopic Reference Method
The sensitivity and specificity values from the 135 specimens (RBC fragments percentage) from the ADVIA 120 were compared with those from the expert (schistocyte percentage). For microscopic examination, a threshold of 0.2% was required to confirm the presence of schistocytes in the specimen, taking into account possible artifacts resulting from blood collection or smearing technique (>0.2%, positive result; ≤0.2%, negative result 6 ). The variation in sensitivity and specificity is shown in ❚Table 1❚. From these values, an ROC curve was drawn ❚Figure 2❚. Its interpretation permitted establishment of 0.25% of RBC fragments as the threshold value of maximum sensitivity (sensitivity, 100%; specificity, 20%). The 0.25% threshold indicated that every value of 0.25% or less was negative and every value of more than 0.25% was positive.
Relationship Between Platelet Counts and Schistocyte Percentages
The mean platelet count was 136 × 10 3 /µL (136 × 10 9 /L; median, 63 × 10 3 /µL [63 × 10 9 /L]; range, 5-836 × 10 3 /µL [5-836 × 10 9 /L]). As we plotted the platelet count and the schistocyte percentage of each sample, no correlation was observed ❚Figure 3A❚. Only when samples with schistocyte percentages of more than 2% were taken into account (all from patients with TMA), was a tendency toward an inverse correlation between the platelet count and schistocyte percentage observed (r 2 = 0.25; P = .07, slope test) ❚Figure 3B❚.
Impact of Automated Schistocyte Counting on Clinical Practice
Once we determined the threshold value of maximum sensitivity for the automated count (schistocytes, 0.25%), we checked whether the initially suspected diagnosis was confirmed clinically. In other words, was the suspicion of a disease that should have manifested with peripheral blood schistocytosis confirmed? The NPV and PPV are given in ❚Table 2❚ and were calculated for automated and microscopic analyses, according to the previously determined thresholds (0.25% RBC fragments for the ADVIA 120 deduced from the ROC curve and 0.2% schistocytes for microscopic evaluation). However, a review of our data suggested more discriminating thresholds (1% for the ADVIA 120 and 0.5% for microscopic evaluation) that gave an increased PPV without a decreased NPV. In all cases, the NPV of the RBC fragments was high (100% for a threshold of RBC fragments at 0.25% and 96.8% for a threshold at 1.0%). RBC fragments less than the threshold excluded a thrombotic disease: microangiopathy (TTP, HUS, bone marrow-related TTP) or macroangiopathy (heart valve dysfunction).
Discussion
Schistocytes are RBC fragments that usually are identified by optical microscopy on a stained blood smear. 7 Their presence is indicative of hemolysis of mechanical origin (eg, cardiac valve, TMA), and they are one of the biologic indicators leading to its diagnosis. 6 In certain situations, a schistocyte count is desirable, eg, follow-up of TTP, particularly during the period after bone marrow transplantation. 8 The identification and counting of schistocytes should be on demand for emergency requests and for permanent use in the laboratory.
There is a lack of standardization of the fragments that can be classified as schistocytes. 9 In the case of marked anisopoikilocytosis, the theoretical idea of selecting only triangular or helmet-shaped fragments is at odds with the reality of trying to distinguish schistocytes from other atypical fragments on the smear. Intralaboratory and interobserver variations are important. Moreover, the region where the smear is scanned influences their identification, because the angular fragments have a tendency to become spherical when smeared (microspheroschistocytes at the smear ends). 10 Finally, in the actual counting, precision is restricted because of the limited number of RBCs that are counted (several hundred).
The lack of agreement among biologists on a practical definition and the variation in research practices from one laboratory to another in conducting the observations and performing the counting led the GFHC to prepare, after some thought, a consensus report on the evaluation of schistocytes based on the microscopic observation of blood smears. 4 The good agreement between observers was evidence that the standardization of microscopic counting of schistocytes was possible (application of a validated reference method, GFHC, in a workshop held before this study). Automated hematology analyzers, by virtue of their ability to analyze the physical and chemical properties of thousands of cells, are an alternative to counting under the microscope. The analysis is observer-independent, has better reproducibility, and is suited to permanent, routine use.
By using the SYSMEX Roche technology (Kobe, Japan), Jiang et al 11 studied small RBCs devoid of RNA in the reticulocyte channel. Modeling permitted determination of the probable number of schistocytes on the basis of the number of events in that zone. This model was applied to samples from patients with TMA. Good correlation between the count provided by the analyzer and the count obtained by using the microscope demonstrated the validity of the procedure. 5 Nevertheless, it remained indirect, and it was difficult to get the best out of it on a routine basis.
The ADVIA 120 analyzer is a unique system that is capable of counting particles of a size close to or greater than a platelet (threshold, <30 fL) and with a refractive index different from that of a platelet (as a result of its hemoglobin content). 12 It therefore easily includes not only the distribution zone characteristic of schistocytes but also several fragments of uncharacteristic shape (eg, very small microcytes, diverse membrane fragments). It was tempting to exploit these results, based on the hypothesis that the RBC fragments corresponded to true schistocytes, in addition to several fragments derived from RBCs, as well as possible artifacts. We anticipated that we could perform "modeling" of the type y = ax + b, where y represents true schistocytes; x, RBC fragments; and b, constant. But the analyzer was able to quantify schistocytes with a relationship close to y = x for some of the samples, in particular those with a percentage of more than 1.5%. The presence of schistocytes on the ADVIA 120 needs to be confirmed manually owing to the high false-positive rate.
The sensitivity and the specificity of the automated measurement were evaluated. An important point was the absence of false-negative results. This statement must survive the test of time, and the total sensitivity of the analyzer cannot be guaranteed. The false-positive results corresponded most often to slightly elevated percentages (0.2%-0.3%) without real clinical relevance (0.2% represents a practical threshold of positivity, occasional schistocytes observed in nonpathologic samples). These samples were, in fact, samples with substantial poikilocytosis. In the automated analysis, an isotonic reagent makes the RBCs sphereshaped, and some fragments or very small RBCs could be classified in the same category as the schistocytes. Because the shape factor was not determined, the instrument retained only the volume and refractive index criteria to characterize these RBC fragments, contrary to microscope examination, in which shape was the determining factor. This could explain why, for a sensitivity of 100%, the specificity was only 20%, signifying that 80% of the "automated" positive results were wrongly considered as real "microscopic" positives. Furthermore, a very shifted result illustrated the limits of the analyzer in terms of specificity (smears characterized by anisopoikilocytosis and numerous nonschistocytic fragments; see the "Results" section).
We found no inverse variation between the schistocyte percentage and the platelet number. Only a schistocyte percentage of more than 2% had a trend toward a lower platelet count. Although nonsignificant, a negative correlation between the schistocyte percentage and the number of platelets has been suspected. 5 In a reference series, a relationship between the severity of thrombocytopenia at diagnosis and overall survival was suspected, 2 but no schistocyte percentage was performed. Our results confirmed that if a high schistocyte percentage can be observed in TMA, little relationship, if any, with a proportionately low platelet number can be deduced.
The more clinically oriented retrospective study comparing automated schistocyte counting with presence or absence of thrombotic disease showed that the 100% NPV was adapted to the calculated thresholds (0.25% of RBC fragments for the ADVIA 120 and 0.2% for microscopic examination). This robust NPV was linked to a poor PPV (23% for the ADVIA 120). To ameliorate the balance of NPV and PPV, we were able to determine more precisely 2 thresholds that gained specificity and PPV without decreasing the sensitivity and NPV too much (1% for the ADVIA 120 and 0.5% for microscopic examination). In our hands, the clinical features correlated particularly with negative automated schistocyte counts, and the apparently high NPV ruled out thrombotic disease such as TTP and HUS.
The determination of RBC fragments by the ADVIA 120 analyzer fulfilled the following criteria: good agreement with the reference measurement, absence (to be confirmed) of false-negative results, and good sensitivity. Nevertheless, the automated results needed confirmation by microscopic examination of a blood smear. The impact of increased numbers of manual peripheral blood smear reviews for schistocytes on the laboratory workload and workflow remains to be evaluated. 
